Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Sponsor
Georgetown

Protocol Number
CA180-618

To Learn More Call
(201)-510-0950